2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalence
2017
Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?
Kunkel A, Furin J, Cohen T. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? The Lancet Infectious Diseases 2017, 17: e429-e433. PMID: 28533094, DOI: 10.1016/s1473-3099(17)30299-2.Peer-Reviewed Original ResearchConceptsUse of bedaquilineDrug-resistant tuberculosisXDR tuberculosisBedaquiline resistanceCohort study resultsMultidrug-resistant tuberculosisNew combination regimensHigh mortality rateFears of resistanceInfected contactsCombination regimensDrug combinationsPatientsEquivalent outcomesMortality rateAntituberculosis drugsBedaquilineTuberculosisNovel drugsDrug bedaquilineDrugsDiseasePopulation implicationsResistance concernsGreat need
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply